Springer Nature
13148_2019_681_MOESM1_ESM.tif (440.07 kB)

Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Download (440.07 kB)
posted on 2019-05-29, 05:00 authored by Min-Wu Chao, Li-Hsun Chang, Huang-Ju Tu, Chao-Di Chang, Mei-Jung Lai, Yi-Ying Chen, Jing-Ping Liou, Che-Ming Teng, Shiow-Lin Pan
Figure S1. Cytotoxic effect of combination HDACi with MEK inhibitors in BxPC-3 and PANC-1 cells. (A, B) BxPC-3 cells were treated with DMSO, MPT0E028 (E028)/SAHA, PD98059 (PD), or MPT0E028/SAHA plus PD98059 with indicated concentration for 72 h. (C, D) PANC-1 cells were treated with DMSO, MPT0E028/SAHA, trametinib (T), or MPT0E028/SAHA plus trametinib with indicated concentration for 72 h. Left panels: Cell viability was determined by MTT assay. Right panels: Combination index (CI) and fraction affected (Fa) are calculated by CompuSyn software. T0.1 and T1 were represented here as trametinib 0.1 μM and 1 μM. (TIF 440 kb)


Ministry of Science and Technology of Taiwan